Last reviewed · How we verify

Propofol,midazolam

Shandong Provincial Hospital · FDA-approved active Small molecule ✓ Verified Jun 2026 Quality 2/100

Propofol,midazolam is a Small molecule drug developed by Shandong Provincial Hospital. It is currently FDA-approved.

Propofol and midazolam are both used for intravenous sedation, with propofol being a positive allosteric modulator of the GABA-A receptor, an anion channel. These medications have been studied in various clinical trials, including those for traumatic brain injury, acute ischemic stroke, and nerve block, among other conditions.

At a glance

Generic namePropofol,midazolam
SponsorShandong Provincial Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Propofol,midazolam

What is Propofol,midazolam?

Propofol,midazolam is a Small molecule drug developed by Shandong Provincial Hospital.

Who makes Propofol,midazolam?

Propofol,midazolam is developed and marketed by Shandong Provincial Hospital (see full Shandong Provincial Hospital pipeline at /company/shandong-provincial-hospital).

What development phase is Propofol,midazolam in?

Propofol,midazolam is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing